SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
NMRA reported Third Quarter 2026 results. The price and volatility reaction is pending.
NMRAearnings

Earnings reactions, page 2

Neumora Therapeutics, Inc. (NMRA) Q3 FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • As of September 30, 2026, Neumora had cash and cash equivalents of $85.7 million.
  • Research and development expenses for the third quarter of 2026 were $22.6 million, compared to $40.5 million for the third quarter of 2025.
  • General and administrative expenses for the third quarter of 2026 were $10.8 million, compared to $12.2 million for the third quarter of 2025.
  • Net loss for the third quarter of 2026 was $34.4 million, compared to $56.8 million for the third quarter of 2025.
  • Net loss per share, basic and diluted, was $0.18 for the third quarter of 2026, compared to $0.35 for the third quarter of 2025.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →